ClinicalTrials.gg
TerminatedNCT03426137Updated Apr 27, 2021Results posted

Relieving Acute Pain (RAP) Study: A Pilot Study

A Phase 2 interventional study of Oxycodone and Ketorolac in Trauma, Opioid Use and Spine Fusion, sponsored by University of Maryland, Baltimore. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The focus of the project has shifted to publishing a protocol for future trials because we were unable to recruit. Three participants signed the consent forms but withdrew before the randomization.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The United States (US) faces a crisis of pain management. According to the 2012 National Health Interview Survey, almost 50 million adults in the US reported having significant chronic or severe pain (Nahin 2015). Doctors in the US still prescribe opioids across the board for pain despite a growing recognition of an epidemic of opioid overdose and use disorder. Few solutions have been successfully proposed and implemented. Placebos represent a novel and potentially fruitful means of addressing this issue. However, clinicians often use placebos deceptively and with little rationale or evidence of benefit, making their use ethically problematic. In contrast with their typical current use, a provocative line of research suggests that placebos can be intentionally exploited to extend analgesic therapeutic effects. Recently, we reviewed a database of placebo studies including 22 studies in both animals and humans hinting of evidence that placebos may work as a dose extender of active painkillers. Placebos given after repeated administration of active treatments can acquire medication-like effects based on learning mechanisms.

Here, we will test if dose-extending placebos are effective in relieving clinical acute pain in opioid patients with traumatic pain. Patients will be randomized to three arms. Arm 1 will be a Full Dose (FD) group, which will receive all NSAIDs as described in the Guidelines for NSAID use in Orthopedic Patients and Oxycodone (5mg). Arm 2 will be a Partial Reinforcement (PR) group, which will receive NSAIDs, Oxycodone (5mg), and placebos to reach a 50% reduction of the total intake of opioids. Finally, Arm 3 will be a Control (C) group receiving NSAIDs and placebos. Patients will be assigned to one of three arms according to a 1:1:1 schedule of randomization. Study IDs will be generated by the pharmacy and blinding will occur by ensuring that oxycodone and placebos look, smell, and taste identical. Rescue therapy will be provided as needed. This novel prospect of placebo use has the potential to change our general thinking about painkiller treatments, the typical regimens of painkiller applications, and the ways in which treatments are evaluated.

Read the detailed description

Overview:

We will screen 500 patients from the Shock Trauma Center to recruit a total of 159 (53 per arm) to participate in a pilot study aimed at reducing use of opioids. Participants will meet all of the eligibility criteria and none of the exclusion criteria. After enrollment, participants will be blindly allocated to one of three randomization arms by means of de-identified Study IDs corresponding to treatment arms. Study IDs will be generated by the pharmacy and blinding will be ensured by creating study drugs that look, smell, and taste identical. The pharmacy will create and dispense identical study drugs in terms of appearance, smell, and taste. Only the blinding coordinator will know the identity of patients in each treatment arm. Arm 1 will be a Full Dose (FD) group, which will receive Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), dosed in accordance with the University of Maryland Shock Trauma Center (STC) Guidelines for NSAIDs and Oxycodone (5mg). Arm 2 will be a Partial Reinforcement (PR) group, which will receive NSAIDs, Oxycodone (5mg), and placebos to reach a 50% reduction of the total intake of opioids. Finally, Arm 3 will be a Control (C) group receiving NSAIDs and placebos. Patients will be assigned to one of these three arms according to a 1:1:1 schedule of randomization. The patient will start receiving study medication as part of his or her pain management as soon as possible after admission to the hospital and enrollment in the study (ideally as their first dose of pain-management medication). Rescue therapy will be provided as needed.

All enrolled patients will receive an Adult Pain Management Service (APMS) consult. APMS will work with the study and clinical teams to ensure that all treatment protocols are met, and be available to address any issues that may arise. The APMS provider will work with the primary service to determine the most effective NSAID as described in their guidelines.

Other than the study medication (Oxycodone and placebo), all participants will be treated in accordance with the current standard of care at the University of Maryland Shock Trauma Center. This includes intravenous Toradol every 8 hours for 24 hours followed by oral NSAIDs round the clock until pain is minimal. The timing of administration will be the same for participants in all three arms - they will receive their arm's treatment (Oxycodone, Oxycodone alternating with placebo, or no additional medication beyond standard of care NSAIDs) round the clock for the first 24 hours followed by every hours for the remainder of hospitalization. All patients will receive intravenous Dilaudid every hour for rescue or break through pain. In addition, all patients will be discharged on Oxycodone tablets (5mg) every 3 hours as needed.

In Arm 2, the first four doses of study drug will be Oxycodone (5mg) to condition them to its effects. Afterwards, they will receive alternating Oxycodone (5mg) and placebo according to one of four repeating sequences. During data analysis, we will test whether the sequence of administration has an effect on outcomes. Participants in Arm 2 will never receive more than 2 doses of placebo in a row. This administration schedule will be repeated for the remainder of hospitalization.

Prior to patients' enrollment:

The intent of this study is to enroll 159 patients with trauma into this study to compare strategies to reduce opioid use during the management of acute pain. Patients will be screened on admission to the Shock Trauma Center. Eligible patients will meet all of the inclusion criteria and none of the exclusion criteria. Patients with trauma will be considered for enrollment and be flagged for screening. A plan by the primary service to adhere to The Shock Trauma Protocol for NSAID use is also a requirement for enrollment. Eligible participants will be informed and have the opportunity to discuss the nature of the study, potential for treatment allocation, and risk/benefits. For those who agree to participate, the approved Informed Consent Form and HIPAA authorization form will be signed. The research staff will explain to the participant what tasks they are expected to complete during this study, answer any questions they may have, and ensure comprehension by completing the Informed Consent Checklist, which asks participants to verbally report their understanding of the study purpose and procedures, among other key points.

Allocation to treatment group:

After the participant discusses and signs the consent form, a staff member will call the pharmacy to inform them of the participant's de-identified Screening number. The pharmacy will then randomly assign that participant a Study ID corresponding randomly to one of the three treatment groups and handle drug logistics (sourcing, processing, and administration) for the remainder of Phase I. The patient will start receiving the study drug within 24 hours of being able to take narcotics, ideally as his/her first narcotic medication. All staff involved with the protocol will be fully trained on it and will be given study team member emergency contacts in case of incident.

Blinding:

Oxycodone and Placebo will be identical in terms of appearance, taste, and smell so as to keep both the investigators and participants blind to their treatment allocation. Oxycodone and placebo oral suspensions will be manufactured by the IDS. Oxycodone solution will be made from tablets to ensure blinding. In this way, both Oxycodone and placebo will look identical for taste, color, and smell. This will help not only to blind the study, but also facilitate study drug administration given that patients may be intubated. All research personnel, aside from the pharmacists and team members responsible for final review and write-up of the study, will be blinded to participants' treatment groups. The pharmacy will dispense medications for each participant that will correspond with their allocated treatment group. For participants in the Partial Reduction group (Arm 2), the pharmacy will dispense the study drug. In summary, participants in Arm 2 will receive four doses of Oxycodone (5mg) followed by one of four repeating schedules of administration alternating between Oxycodone (5mg) and placebo.

Hospitalization window (Enrollment - End of Hospitalization):

Pain ratings will be recorded as usual within 20 to 90 minutes after each study drug administration. Also, participants will be given the option to complete a set of psychological questionnaires during the time in the hospital or by the time of their first follow-up visit. Questionnaires unrelated to pain will be optional. Although we cannot change the wording of our validated pain questionnaires, staff will be trained to use the phrasing such as "how well they are able to perform their daily activities, how well they are able to interact with visitors/family, and how well they are sleeping" whenever possible, and that surveys andquestions during the follow-up phase will also take this non-pain-centric approach.

Discharge:

Participants will be monitored for subsequent use of opioids at the first post-discharge visit (at approximately 2 weeks) and within month 1, 3, and 6 for follow-ups. The research team via calls, letters, emails, or texts. REDCap, Qualtrics / MetricWire will be used to facilitate the communication via text and emails. The team member will ask the participant questions about their health and medication use. In addition, a phone application may be developed or the data collection system Qualtrics used to gather information about participants' medication use and health during the follow-up period. Although the wording of the validated Pain Questionnaires we will use during hospitalization cannot be changed, during the follow-up phase we will aim to frame questions about pain intensity and interference with function in such a way as to avoid nocebo effects (i.e. asking how well they are able to perform their daily activities, how well they are able to interact with visitors/family, and how well they are sleeping instead of how much pain are they experiencing).

Duration of the clinical trial:

Hospitalization window (starting as soon after admission as possible for a projected minimum of 2 days), with follow-up at approximately 2 weeks (coinciding with their first post-discharge visit with their clinician), and months 1, 3, and 6.

Rescue plan:

All patients will have the same rescue medicine available for break through pain; intravenous Dilaudid every hour.

Participants in each of the three randomization arms will have access to opioid rescue medication (Dilaudid) as needed via a standing order for breakthrough pain rated as Severe. The rate of use pf rescue therapy will be evaluated as a primary endpoints. Participants who request more than 3 doses of rescue medication in a row will be withdrawn from the study and referred to APMS for further pain management.

Primary and secondary outcomes. To be measured daily during hospitalization

1.) Acute clinical and functional pain / acute pain improvement; opioid intake; rate of request of rescue therapies.

Primary and secondary outcomes. To be measured daily during the follow-up.

  1. Use (frequency and intensity) of opioid prescriptions
  2. Development of dependence and/or addiction problems
02

Conditions studied

  • Trauma
  • Opioid Use
  • Spine Fusion

Browse trials for

Keywords

  • Oxycodone
  • Placebo
  • Expectancy Induced Analgesia
  • NSAID
03

In context

Wounds and Injuries

2,220 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's enrollment of 3 is below the median of 70 across 1,425 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.

Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65
  • Admission to The Shock Trauma Center within 72 hrs
  • Any trauma requiring inpatient opioid medication
  • Plan by primary service to follow the Shock Trauma Guidelines for Acute Pain in Orthopedic Injury
  • Predicted length of stay greater than or equal to 2 days

Exclusion criteria

Exclusion Criteria:

  • Non English speaking
  • Spine cord injury
  • Severe Traumatic brain injury (based on a Glascow Coma Scale of 8 or less)
  • Patient-controlled analgesia
  • Admission Creatinine > 1.4
  • History of chronic kidney disease
  • Heroin use in the 3 months prior to admission (patient self-report)
  • Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, mania, autism) and /or psychiatric condition leading to treatment and/or hospitalization within the last 1 year.
  • Positive toxicology screen for methadone not prescribed during current hospitalization
  • Pregnancy or breast feeding
  • to NSAIDs, including high risk of bleeding or known severe coronary artery disease
  • Injuries deemed non survival.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Full Dose (FD)

    Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.

    Drug: Oxycodone · Drug: Ketorolac

  • Placebo comparator
    PR (Partial Reinforcement)

    Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.

    Drug: Oxycodone · Drug: Ketorolac · Other: Placebo

  • Placebo comparator
    C (Control)

    Participants in this group will receive NSAIDs and placebo pills

    Drug: Ketorolac · Other: Placebo

Interventions

  • 5mg Oxycodone in oral solution given every 3 hours

    Also known as: Oxycodone Hydrochloride

  • toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.

    Also known as: Toradol

  • OtherPlacebo

    Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet

    Also known as: OraSweet

06

What researchers measure

Primary outcomes

  1. Pain Self-reports

    Collected on a visual analogue scale, with 0 being "no pain" and 100 being "maximum pain tolerable"

    Time frame: Day 1-7, Week 2, Months 1, 3 and 6

07

Results

Posted Mar 16, 2020
Limitations and caveats
Early termination due to logistical and funding issues, which lead to no analyzable data. A protocol paper has been published should other investigators wish to use the study design (DOI: 10.1136/bmjopen-2019-030623).

Participant flow

Three participants were consented from University of Maryland Shock Trauma Center, per protocol, between 3/17/2019 to 3/30/2019. All three withdrew before randomization or starting any study procedures.

Participant flow — Overall Study
MilestoneFull Dose (FD)PR (Partial Reinforcement)C (Control)
Started000
Completed000
Not completed000

Outcome measures

PrimaryPain Self-reports

Collected on a visual analogue scale, with 0 being "no pain" and 100 being "maximum pain tolerable"

Time frame:
Day 1-7, Week 2, Months 1, 3 and 6

No measurements were reported for this outcome.

Adverse events

Collected over All three participants enrolled gave written consent to participate in the study and signed the HIPAA form, but withdrew before starting any study procedures.These 3 withdrawals were handled per protocol. Therefore, there was no time period over which adverse events were collected.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Dose (FD)———
PR (Partial Reinforcement)———
C (Control)———

Baseline characteristics

The three participants who gave written consent to participate in the study and signed the HIPAA form withdrew before randomization or starting any study procedures. Therefore there is no data available to report.

Age, Continuous
Age, Continuous(years)Full Dose (FD)PR (Partial Reinforcement)C (Control)Total
Sex: Female, Male
Sex: Female, MaleFull Dose (FD)PR (Partial Reinforcement)C (Control)Total
Female————
Male————
Race (NIH/OMB)
Race (NIH/OMB)Full Dose (FD)PR (Partial Reinforcement)C (Control)Total
American Indian or Alaska Native————
Asian————
Native Hawaiian or Other Pacific Islander————
Black or African American————
White————
More than one race————
Unknown or Not Reported————
Pain report
Pain report(units on a scale)Full Dose (FD)PR (Partial Reinforcement)C (Control)Total
08

Study locations

1 site
  • University of Maryland
    Baltimore, Maryland 21201-1512, United States
09

References and documents

Publications

  • Chen EY, Marcantonio A, Tornetta P 3rd. Correlation Between 24-Hour Predischarge Opioid Use and Amount of Opioids Prescribed at Hospital Discharge. JAMA Surg. 2018 Feb 21;153(2):e174859. doi: 10.1001/jamasurg.2017.4859. Epub 2018 Feb 21. PubMed 29238810 ↗
  • Hah J, Mackey SC, Schmidt P, McCue R, Humphreys K, Trafton J, Efron B, Clay D, Sharifzadeh Y, Ruchelli G, Goodman S, Huddleston J, Maloney WJ, Dirbas FM, Shrager J, Costouros JG, Curtin C, Carroll I. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial. JAMA Surg. 2018 Apr 1;153(4):303-311. doi: 10.1001/jamasurg.2017.4915. Erratum In: JAMA Surg. 2018 Apr 1;153(4):396. doi: 10.1001/jamasurg.2018.0004. JAMA Surg. 2022 Jun 1;157(6):553. doi: 10.1001/jamasurg.2022.1392. PubMed 29238824 ↗
  • Howard R, Waljee J, Brummett C, Englesbe M, Lee J. Reduction in Opioid Prescribing Through Evidence-Based Prescribing Guidelines. JAMA Surg. 2018 Mar 1;153(3):285-287. doi: 10.1001/jamasurg.2017.4436. Erratum In: JAMA Surg. 2019 Mar 1;154(3):272. doi: 10.1001/jamasurg.2019.0070. PubMed 29214318 ↗
  • Zelcer S, Kolesnikov Y, Kovalyshyn I, Pasternak DA, Pasternak GW. Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Res. 2005 Apr 8;1040(1-2):151-6. doi: 10.1016/j.brainres.2005.01.070. PubMed 15804436 ↗
  • Vanegas H, Vazquez E, Tortorici V. NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System. Pharmaceuticals (Basel). 2010 Apr 29;3(5):1335-1347. doi: 10.3390/ph3051335. PubMed 27713305 ↗
  • Colloca L, Lee SE, Luhowy MN, Haycock N, Okusogu C, Yim S, Raghuraman N, Goodfellow R, Murray RS, Casper P, Lee M, Scalea T, Fouche Y, Murthi S. Relieving acute pain (RAP) study: a proof-of-concept protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open. 2019 Nov 11;9(11):e030623. doi: 10.1136/bmjopen-2019-030623. PubMed 31719077 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD will only be shared among study team members.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Mar 2019, 6 months.

Results were first posted in Mar 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Feb 8, 2018
StartActual
Sep 17, 2018
Primary completionActual
Mar 30, 2019
CompletionActual
Jan 21, 2020
Results first posted
Mar 16, 2020
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03426137
Responsible party
Luana Colloca (Associate Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Feb 8, 2018
Start date
Sep 17, 2018
Primary completion
Mar 30, 2019
Completion
Jan 21, 2020
Results posted
Mar 16, 2020
Last update
Apr 27, 2021

Study contacts

Luana Colloca, MD/PHD/MS
principal investigator · University of Maryland Baltimore School of Nursing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion